Entry41.21→Now40.57
VCYT bullish on Convergent/UroAmp growth driver Open original source
VCYT Veracyte, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
22:27
Sep 14
Sep 14
VCYT bullish on Convergent/UroAmp growth driver
The author argues Veracyte's $150M cash purchase of Convergent Genomics (plus up to $30M in milestones) is a good move, with the UroAmp urine-based tumor DNA bladder cancer test as the key asset. The mechanism is that if Veracyte can scale UroAmp and secure wider adoption and reimbursement, it becomes a meaningful new growth driver for the company. The author states they are more bullish on VCYT after the deal, with no explicit time horizon given. The main stated risk is whether they overpaid for the acquisition.
HIGH
About VCYT Investor Commentary
Across the available history and selected sources, Buzzberg tracks VCYT (Veracyte, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/a_moron_in_a_hurry.